Role of-675 4G/5G in the plasminogen activator inhibitor-1 gene and-308G/A tumor necrosis factor-α gene polymorphisms in obese argentinean patients

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 5, 2012, Pages 372-375

  Wingeyer, Silvia D Perés ^a   Graffigna, Mabel N ^b   Belli, Susana H ^b   Benetucci, Jorge ^a   De Larrañaga, Gabriela F ^a  

^a HOSPITAL F J MUÑIZ   (Argentina)

^b HOSPITAL DURAND   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; OBESITY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST CIRCUMFERENCE;

ADULT; ARGENTINA; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INSULIN RESISTANCE; MALE; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84861491007     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0253     Document Type: Article

References (38)

1. Alessi M, Juhan-Vague I (2006) PAI-and the metabolic syndrome: links, causes and consequences. Arterioscler Thromb Vasc Biol 26:2200-2207.
2. Baralle M, Baralle F (2006) Genetics and molecular biology: single nucleotide polymorphism associations and their functional significance. Curr Opin Lipidol 17:360-362.
3. Bastarrachea RA, Shelley AC, Comuzzie AG (2004) Genomics of body weight regulation: unraveling the molecular mechanisms predisposint to obesity. Med Clin (Barc) 123:104-117.
4. Bensen JT, Hsu FC, Brown WM, et al. (2004) Association analysis of the plasminogen activator inhibitor-1 4G/5G polymorphism in Hispanics and African Americans: the IRAS family study. Hum Hered 57:128-137.
5. Bouchard C (1993) Genes and body fat. Am J Human Biol 5:425-432.
6. Brand E, Schorr U, Kunz I, et al. (2001) Tumor necrosis factor-a-308 polymorphism in obese Caucasians. Int J Obes 25: 581-585.
7. Cooper DN, Nussbaum RL, Krawczak M (2002) Proposed guidelines for papers describing DNA polymorphism-disease associations. Hum Genet 110:207-208.
8. Dahlman I, Arner P (2007) Obesity and polymorphisms in genes regulating human adipose tissue. Int J Obes 31:1629-1641.
9. Dalziel B, Gosby AK, Richman RM et al. (2002) Association of the TNF G/A promoter polymorphism with insulin resistance in obesity. Obes Res 10:401-407.
10. Estellés A, Dalmau J, Falcó C, et al. (2001) Plasma PAI-1 levels in obese children-effect of weight loss and influence of PAI1 promoter 4G/5G genotype. Thromb Haemost 86:647-652.
11. Falk G, Almquist A, Nordenhem A, et al. (1995) Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 9:170-174.
12. Fernandez-Real JM, Gutierrez C, Ricart W, et al. (1997) The TNF-a gene NCO I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes 46:1468-1471.
13. Fisler JS, Warden CH (2007) The current and future search for obesity genes. Am J Clin Nutr 85:1-2.
14. Ford Runge C (2007) Economic consequences of the obese. Diabetes 56:2668-2672.
15. Freeman M, Mansfield M, Barret JH, Grant PJ. (2002) Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability. Arterioscler Thromb Vasc Biol 22:506-510.
16. Gustafson B (2010) Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb. 17:332-341.
17. Hoffstedt J, Andersson IL, Persson L, et al. (2002) The common-675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetolog?́a 45:584-587.
18. Hoffstedt J, Eriksson P, Hellström L et al. (2000) Excessive fat accumulation is associated with the TNFa-308 G/A promoter polymorphism in women but not in men. Diabetologia 43:117-120.
19. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adiposse expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91.
20. Lafontan M, Girard J (2008) Impact of visceral adipose tissue on liver metabolism. Part I: Heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabetes Metab 34:317-327.
21. Lijnen HR, Alessi MC, Van Hoef B, et al. (2005) On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 3:1174-1179.
22. Ma LJ, Mao SL, Taylor KL, et al. (2004) Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53:336-346.
23. Mavri A, Bastelica D, Poggi M, et al. (2007) Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women. Thromb Haemost 97:62-66.
24. Morange PE, Alessi MC, Verdier M, et al. (1999) PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thrombo Vasc Biol 19:1361-1365.
25. Naran N, Chetty N, Crowther N (2008) The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity. Atherosclerosis 196:155-163.
26. Nieto-Vazquez I, Fenandez-Veledo S, Krämer DK, et al. (2008) Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiology Biochem 114:183-194.
27. Orr N, Bekke V, Chanock S (2006) Genetic association studies: marking them well. J Infect Dis 194:1475-1477.
28. Pihlajamä ki J, Ylinen M, Karhapää P, et al. 2003 The effect on the-308A allele of the TNF-a gene on insulin action is dependent on obesity. Obes Res 11 912-917.
29. Romeo S, Sentinelli F, Capici F, et al. (2001) The G-308A variant of the tumor necrosis factor (TNF-a) gene is not associated with obesity, insulin resistance and body fat distribution. BMC Med Genet 2:10.
30. Samad F, Uysal KT, Wiesbrock SM, et al. (1999) Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 96:6902-6907.
31. Santos M JL, Patiñ o G A, Angel B B, et al. (2006) Association between tumor necrosis factor-alpha promoter polymorphisms and type 2 diabetes and obesity in Chilean elderly women. Rev Med Chile 134:1099-1106.
32. Sartori MT, Vettor R, De Pergola G, et al (2001) Role of the 4G/5G polymorphism of PAI-1 promoter on PAI-1 levels in obese patients. Thromb Haemost 86:1161-1169.
33. Solá E, Vayá A, España F, et al. (2008) Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of weight loss and influence of 4G/5G polymorphism. Thrombos Res 122:320-327.
34. Sookoian SC, Gonzalez C, Pirola C (2005) Meta-analysis on the G-308A tumor necrosis factor a gene variant and phenotypes associated with the metabolic syndrome. Obes Res 13:2122-2131.
35. Stephens JC, Schneider JA, Tanguay DA, el al. (2001) Haplotype variation and linkage disequilibrium in 313 human genes. Science 293:489-493.
36. Subramanian SV, Perkins JM, Ozaltin E, et al. (2011) Weight of nations: a socioeconomic analysis of women in low-to middleincome countries. Am J Clin Nutr 93:413-421.
37. Walston J, Seibert M, Yen CJ, el al. (1999) Tumor necrosis factor-a 238 and-308 polymorphisms do not associate with traits related to obesity and insulin resistance. Diabetes 48:2096-2098.
38. Welsh P, Polisecki E, Robertson M, el al. (1997) Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94:3195-3199.